Bio-Path reports interim Phase II data for AML candidate
Bio-Path Holdings Inc. (NASDAQ:BPTH) reported interim data from 17 evaluable patients with previously untreated acute myelogenous leukemia (AML) who are ineligible for intensive induction therapy in a Phase II trial showing that prexigebersen (BP1001) plus low-dose cytarabine led to four complete remissions and four cases of stable disease. The company said the open-label, U.S. trial will be expanded to a total of 54 patients.
The trial's primary endpoint is complete remission rate. Secondary endpoints include overall survival (OS), time to response, duration of response, safety and pharmacokinetics...
BCIQ Company Profiles
BCIQ Target Profiles